Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

6986 results

Sort By:

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Study ID: NCT06207123
Start Date: 2024-09-13
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

15

Intervention / Treatment

LP-118

Ponatinib

Vincristine

Dexamethasone

Methotrexate

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Study ID: NCT06898996
Start Date: 2025-07-10
End Date: 2029-07-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

400

Intervention / Treatment

Fecal immunochemical test

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Study ID: NCT05860296
Start Date: 2023-05-31
End Date: 2028-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

92

Intervention / Treatment

SLC-391

pembrolizumab

Sponsor

SignalChem Lifesciences Corporation

Source: clinicaltrials.gov

Share:
Add to list

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Study ID: NCT05589896
Start Date: 2024-08-16
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

12

Intervention / Treatment

Ossium HPC Marrow, Bone Marrow Transplant

Pre-transplant conditioning - Myeloablative (MAC)

Pre-transplant conditioning - Reduced Intensity (RIC)

Post-transplant treatment

Sponsor

Bone Health, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Study ID: NCT03300830
Start Date: 2017-12-20
End Date: 2037-06-25
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

280

Intervention / Treatment
Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Study ID: NCT04669171
Start Date: 2021-07-05
End Date: 2032-05-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

EO2463

lenalidomide

rituximab

Sponsor

Enter me

Source: clinicaltrials.gov

Share:
Add to list

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Study ID: NCT06171139
Start Date: 2023-12-01
End Date: 2027-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment

Counseling Tool

Questionnaires

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Study ID: NCT05736029
Start Date: 2022-11-07
End Date: 2028-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

350

Intervention / Treatment

blood, stool and tissue samples collection

Sponsor

OncoHost Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Study ID: NCT05879367
Start Date: 2023-07-24
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

66

Intervention / Treatment

Eflornithine (Dose Level 1)

Eflornithine (Dose Level 2)

Eflornithine (Dose Level -1)

Temozolomide

Sponsor

Orbus Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Study ID: NCT05094336
Start Date: 2022-02-01
End Date: 2028-06-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

649

Intervention / Treatment

AMG 193

Docetaxel

Comparator AMG 193 Test Tablet

Sponsor

Amgen

Source: clinicaltrials.gov

Share:
Add to list